COMPANY
Gilgamesh Pharma
NIH awards 1
- NIH award 6UG3DA060053-03 FY2025: $1,851,123 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI MAREK, GERARD JOSEPH; recipient as written: GILGAMESH PHARMA INC, NEW YORK, NY. Development of a Safer and More source ↗
Funding and NIH signals
- SEC Form D raise Raised $2.25M (Form D filed Mar 31, 2026); +2 other Form D filings in the last 12 months. SEC Form D 0002107396-26-000004 (Mar 31, 2026)
Evidence (3 events)
- Mar 31, 2026 · SEC Form D 0002107396-26-000004
Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-03-31; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-27; Types of Securities Offered: Option/warrant, Other (Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.); Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 2250000; Federal exemptions: 06b - Mar 24, 2026 · SEC Form D 0002107396-26-000003
Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-03-24; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-09; Types of Securities Offered: Equity, Other (Shares of Preferred Stock of Issuer and the shares of capital stock of Issuer into which such shares of Preferred Stock may convert.); Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 60000000; Federal exemptions: 06b - Feb 4, 2026 · SEC Form D 0002107396-26-000002
Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-02-04; Industry Group: Pharmaceuticals; Date of First Sale: 2026-01-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6090946; Total Amount Sold: 6090946; Federal exemptions: 06b
- Mar 31, 2026 · SEC Form D 0002107396-26-000004
- NIH award NIH awarded $1.85M (NIH grant 6UG3DA060053-03, change of grantee, notice May 13, 2026). NIH RePORTER 6UG3DA060053-03 (May 13, 2026)
Evidence (1 event)
- May 13, 2026 · NIH RePORTER 6UG3DA060053-03
Organization: GILGAMESH PHARMA INC; City/State: NEW YORK, NY; Project number: 6UG3DA060053-03; Activity code: UG3; Fiscal year: 2025; Award notice date: 2026-05-13; FY total cost (award amount): 1851123; Administering IC: National Institute on Drug Abuse; Project title: Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder; Organization type: Domestic For-Profits
- May 13, 2026 · NIH RePORTER 6UG3DA060053-03